China-based biotech startups GeneQuantum and InxMed have signed a collaboration agreement. GeneQuantum has granted non-exclusive licensing of its proprietary  conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC (antibody-drug conjugate) drugs.

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform. This will support InxMed in developing innovative ADC drugs.

The agreement was signed following the successful concept validation results of the candidate drugs developed by both parties. 

InxMed will be responsible for the research, development (R&D), manufacturing, and commercialisation of the ADC candidate molecules. 

This collaboration will enable both parties to leverage their respective technological advantages and resources, accelerate the research and development process of innovative ADC drugs, and provide more treatment options for patients worldwide.